Lockney Natalie A, Yang Joanna C
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida.
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.
Adv Radiat Oncol. 2020 Jun 20;5(5):809-816. doi: 10.1016/j.adro.2020.06.001. eCollection 2020 Sep-Oct.
The backbone of treatment for patients with advanced-stage Hodgkin lymphoma is systemic therapy. The use of radiation therapy as a component of combined-modality treatment in this setting is controversial. In this review, we describe the data in support of and against the use of radiation therapy for stage III and IV Hodgkin lymphoma. Specifically, we review the data for the use of radiation therapy in the consolidation and partial-response settings, including for patients with initial bulky disease. We also discuss the use of radiation therapy in the era of more modern systemic therapies, including checkpoint inhibitors and brentuximab vedotin.
晚期霍奇金淋巴瘤患者治疗的核心是全身治疗。在这种情况下，将放射治疗作为综合治疗的一部分使用存在争议。在本综述中，我们描述了支持和反对在Ⅲ期和Ⅳ期霍奇金淋巴瘤中使用放射治疗的数据。具体而言，我们回顾了在巩固治疗和部分缓解情况下使用放射治疗的数据，包括初始有大包块病变的患者。我们还讨论了在更现代的全身治疗时代，包括检查点抑制剂和本妥昔单抗，放射治疗的使用情况。
